Cerebrospinal fluid (CSF) biomarkers reflecting AD-related pathological changes such as CSF phosphorylated Tau protein (p-tau) and Beta-amyloid 1-42 (Abeta42), as well as markers of neurodegeneration like total-Tau (t-tau), were identified, validated, and employed in established research criteria for the diagnosis of AD [1, 2]. The gene discussed is MAPT; the disease is Alzheimer disease.